BC Extra | Mar 27, 2007
Financial News

Affinium raises $18 million

Infectious disease company Affinium (Toronto, Ontario) raised US$18 million in a series A round led by new investor Forward Ventures. New investors Oxford Bioscience Partners and SV Life Sciences and existing investor Genesys Capital also...
BC Week In Review | Mar 4, 2002
Company News

Affinium Pharmaceuticals deal

Affinium, formerly Integrative Proteomics Inc. , formed chemistry subsidiary Ylektra Inc. The subsidiary will use its selective transformation technology to develop milligram quantities of compounds built around core structures for Affinium's for lead optimization. Affinium Pharmaceuticals...
BC Extra | Feb 26, 2002
Company News

Affinium forms chemistry subsidiary

Affinium (Toronto, Ontario), formerly Integrative Proteomics , formed a chemistry subsidiary called Ylektra. The subsidiary will use its selective transformation technology to develop new compounds and catalysts and to improve production of existing compounds. Ylektra was...
BC Week In Review | Dec 24, 2001
Company News

Integrative Proteomics management update

Integrative Proteomics Inc. , Toronto, Ontario   Business: Proteomics   Hired: Molly Schmid as SVP of antibacterial pharmaceuticals and alliances, formerly senior director of functional genomics and bioinformatics at Genencor International Inc.  ...
BioCentury | Dec 17, 2001
Finance

Ebb & Flow

As the rumor mill churned with news of Amgen taking out Immunex , the size of the combined mega-biotech continued to shrink as AMGN's shares tumbled amid uncertainty over the presumed deal terms. In fact, AMGN's...
BioCentury | Dec 17, 2001
Finance

Ebb & Flow

As the rumor mill churned with news of Amgen taking out Immunex , the size of the combined mega-biotech continued to shrink as AMGN's shares tumbled amid uncertainty over the presumed deal terms. In fact, AMGN's...
BioCentury | Nov 5, 2001
Regulation

Testing the reach of process patents

Recent developments in two patent infringement lawsuits address the ability of companies to claim infringement of their U.S. patents by products made in other countries using the patented material or process and then imported into...
BioCentury | Oct 15, 2001
Finance

Ebb & Flow

Isis filed for a 5 million share follow-on, but market watchers don't believe it marks the start of an underwritten funding window. Rather, the company is selling into strength of its stock price in the...
BC Week In Review | Oct 8, 2001
Company News

Integrative Proteomics, University of Toronto deal

The parties will map the proteomes of pathogenic bacteria. The deal combines Integrative's high throughput mass spectroscopy for protein characterization with the university's bacteriology and mass spectroscopy platforms. The Ontario Research and Development Challenge Fund...
BioCentury | Sep 10, 2001
Emerging Company Profile

Corporate Profile

Integrative Proteomics Inc. Location: Toronto, Ontario Technology: Proteomics and protein structure analysis Disease focus: Antimicrobials Clinical status: NA Founded: 2000 by merger of Chalon Biotech Inc. and Borealis Biosciences Inc. Corporate partners: Aurora Biosciences; Bruker...
Items per page:
1 - 10 of 21
BC Extra | Mar 27, 2007
Financial News

Affinium raises $18 million

Infectious disease company Affinium (Toronto, Ontario) raised US$18 million in a series A round led by new investor Forward Ventures. New investors Oxford Bioscience Partners and SV Life Sciences and existing investor Genesys Capital also...
BC Week In Review | Mar 4, 2002
Company News

Affinium Pharmaceuticals deal

Affinium, formerly Integrative Proteomics Inc. , formed chemistry subsidiary Ylektra Inc. The subsidiary will use its selective transformation technology to develop milligram quantities of compounds built around core structures for Affinium's for lead optimization. Affinium Pharmaceuticals...
BC Extra | Feb 26, 2002
Company News

Affinium forms chemistry subsidiary

Affinium (Toronto, Ontario), formerly Integrative Proteomics , formed a chemistry subsidiary called Ylektra. The subsidiary will use its selective transformation technology to develop new compounds and catalysts and to improve production of existing compounds. Ylektra was...
BC Week In Review | Dec 24, 2001
Company News

Integrative Proteomics management update

Integrative Proteomics Inc. , Toronto, Ontario   Business: Proteomics   Hired: Molly Schmid as SVP of antibacterial pharmaceuticals and alliances, formerly senior director of functional genomics and bioinformatics at Genencor International Inc.  ...
BioCentury | Dec 17, 2001
Finance

Ebb & Flow

As the rumor mill churned with news of Amgen taking out Immunex , the size of the combined mega-biotech continued to shrink as AMGN's shares tumbled amid uncertainty over the presumed deal terms. In fact, AMGN's...
BioCentury | Dec 17, 2001
Finance

Ebb & Flow

As the rumor mill churned with news of Amgen taking out Immunex , the size of the combined mega-biotech continued to shrink as AMGN's shares tumbled amid uncertainty over the presumed deal terms. In fact, AMGN's...
BioCentury | Nov 5, 2001
Regulation

Testing the reach of process patents

Recent developments in two patent infringement lawsuits address the ability of companies to claim infringement of their U.S. patents by products made in other countries using the patented material or process and then imported into...
BioCentury | Oct 15, 2001
Finance

Ebb & Flow

Isis filed for a 5 million share follow-on, but market watchers don't believe it marks the start of an underwritten funding window. Rather, the company is selling into strength of its stock price in the...
BC Week In Review | Oct 8, 2001
Company News

Integrative Proteomics, University of Toronto deal

The parties will map the proteomes of pathogenic bacteria. The deal combines Integrative's high throughput mass spectroscopy for protein characterization with the university's bacteriology and mass spectroscopy platforms. The Ontario Research and Development Challenge Fund...
BioCentury | Sep 10, 2001
Emerging Company Profile

Corporate Profile

Integrative Proteomics Inc. Location: Toronto, Ontario Technology: Proteomics and protein structure analysis Disease focus: Antimicrobials Clinical status: NA Founded: 2000 by merger of Chalon Biotech Inc. and Borealis Biosciences Inc. Corporate partners: Aurora Biosciences; Bruker...
Items per page:
1 - 10 of 21